P
Papagudi Ganesan Subramanian
Researcher at Homi Bhabha National Institute
Publications - 47
Citations - 377
Papagudi Ganesan Subramanian is an academic researcher from Homi Bhabha National Institute. The author has contributed to research in topics: Immunophenotyping & Minimal residual disease. The author has an hindex of 7, co-authored 47 publications receiving 219 citations. Previous affiliations of Papagudi Ganesan Subramanian include Tata Memorial Hospital.
Papers
More filters
Journal ArticleDOI
BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.
Mary Alikian,Gareth Gerrard,Papagudi Ganesan Subramanian,Katherine Mudge,Pierre Foskett,Jamshid S. Khorashad,Ai Chiin Lim,David Marin,Dragana Milojkovic,Alistair Reid,Katy Rezvani,John M. Goldman,Jane F. Apperley,Letizia Foroni +13 more
TL;DR: The methods most widely used in the laboratory to monitor KD mutations in patients with CML including direct sequencing, D‐HPLC, and pyrosequencing are described in a “manual” style.
Journal ArticleDOI
Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000
Prashant Tembhare,Sitaram Ghogale,Nisha Ghatwai,Y. Badrinath,Nikesh Kunder,Nikhil Patkar,Asma Bibi,Gaurav Chatterjee,Brijesh Arora,Gaurav Narula,Shripad Banawali,Nilesh Deshpande,Prathibha Amare,Sumeet Gujral,Papagudi Ganesan Subramanian +14 more
TL;DR: The utility of new markers in improvising MFC‐based MRD detection in BCPALL is studied and the incorporation of additional reliable markers is required for the further improvement of M FC‐ based MRD evaluation.
Journal ArticleDOI
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
Nikhil Patkar,Chinmayee Kakirde,Anam Fatima Shaikh,Rakhi Salve,Prasanna Bhanshe,Gaurav Chatterjee,Sweta Rajpal,Swapnali Joshi,Shruti Chaudhary,Rohan Kodgule,Sitaram Ghoghale,Nilesh Deshpande,Dhanalaxmi Shetty,Syed Hasan Khizer,Hasmukh Jain,Bhausaheb Bagal,Hari Menon,Navin Khattry,Manju Sengar,Prashant Tembhare,Papagudi Ganesan Subramanian,Sumeet Gujral +21 more
TL;DR: In this paper, NGS-MRD was shown to be predictive of inferior outcome in intermediate cytogenetic risk and demonstrated potential in favorable cytogenetics risk AML, and showed a widely applicable, scalable NGSMRD approach that is clinically informative and synergistic to FCM-MRd in AML treated with conventional therapies.
Journal ArticleDOI
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy
Prashant Tembhare,Prashant Tembhare,Harshini Sriram,Harshini Sriram,Twinkle Khanka,Twinkle Khanka,Gaurav Chatterjee,Gaurav Chatterjee,Devasis Panda,Devasis Panda,Sitaram Ghogale,Sitaram Ghogale,Y. Badrinath,Y. Badrinath,Nilesh Deshpande,Nilesh Deshpande,Nikhil Patkar,Nikhil Patkar,Gaurav Narula,Gaurav Narula,Bhausaheb Bagal,Hasmukh Jain,Manju Sengar,Navin Khattry,Shripad Banavali,Shripad Banavali,Sumeet Gujral,Sumeet Gujral,Papagudi Ganesan Subramanian,Papagudi Ganesan Subramanian +29 more
TL;DR: The data demonstrated that CD38 is robustly expressed in T-ALL blasts with a little effect of cytotoxic chemotherapy making it a potentially effective target for antiCD38-Mab therapy.
Journal ArticleDOI
Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia.
Nikhil Patkar,Rohan Kodgule,Chinmayee Kakirde,Goutham Raval,Prasanna Bhanshe,Swapnali Joshi,Shruti Chaudhary,Y. Badrinath,Sitaram Ghoghale,Shraddha Kadechkar,Syed Hasan Khizer,Sadhana Kannan,Dhanalaxmi Shetty,Anant Gokarn,Sachin Punatkar,Hasmukh Jain,Bhausaheb Bagal,Hari Menon,Manju Sengar,Navin Khattry,Prashant Tembhare,Papagudi Ganesan Subramanian,Sumeet Gujral +22 more
TL;DR: It is established that DNA based N PM1 NGS MRD is a highly useful test for prediction of relapse and survival in NPM1mut AML.